Specifically, our in vivo experiments showing a significant but more limited response to erlotinib in LATS1/2 KO group and rapid tumor regrowth after erlotinib treatment support the idea that YAP/TAZ activation plays an important role in therapy resistance and in tumor recurrence. Here, LATS1 is linked to neoplasm.